Verastem (NASDAQ: VSTM) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Verastem to similar businesses based on the strength of its dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.
This table compares Verastem and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a breakdown of current recommendations and price targets for Verastem and its rivals, as provided by MarketBeat.
||Strong Buy Ratings
Verastem currently has a consensus price target of $10.64, suggesting a potential upside of 259.56%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.70%. Given Verastem’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Verastem is more favorable than its rivals.
Earnings and Valuation
This table compares Verastem and its rivals gross revenue, earnings per share and valuation.
Verastem’s rivals have higher revenue and earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Verastem has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Verastem’s rivals have a beta of 2.51, meaning that their average share price is 151% more volatile than the S&P 500.
Institutional & Insider Ownership
28.7% of Verastem shares are held by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 6.5% of Verastem shares are held by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Verastem rivals beat Verastem on 9 of the 13 factors compared.
Verastem Company Profile
Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company’s programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company’s VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company’s VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.